FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) podcast

FDA D.I.S.C.O. Burst Edition: FDA approval of Cabometyx (cabozantinib) for locally advanced or metastatic differentiated thyroid cancer

0:00
3:00
Rewind 15 seconds
Fast Forward 15 seconds
Listen to a soundcast of the September 17, 2021 FDA approval of Cabometyx (cabozantinib) for locally advanced or metastatic differentiated thyroid cancer.

More episodes from "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"